Quick Answer
Nuvalent, Inc. reported Operating Income Loss of -$414.31 million for the year ending 2025.
- Nuvalent, Inc. showed a decrease of -47.8% in Operating Income Loss from 2024 to 2025.
- This data is from Nuvalent, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$4.01 million | Q3 2020: -$4.04 million | Q1 2021: -$6.16 million | Q2 2021: -$9.85 million | Q3 2021: -$12.43 million | Q1 2022: -$17.69 million | Q2 2022: -$18.73 million | Q3 2022: -$20.39 million | Q1 2023: -$30.21 million | Q2 2023: -$34.06 million | Q3 2023: -$38.78 million | Q1 2024: -$52.59 million | Q2 2024: -$65.15 million | Q3 2024: -$76.33 million | Q1 2025: -$94.81 million | Q2 2025: -$104.57 million | Q3 2025: -$112.70 million.
- Over the full 6 years of available data (2020 to 2025), Nuvalent, Inc.'s Operating Income Loss has declined by 2,350.8%.
- Historical annual values: Fiscal year 2025: -$414.31 million | Fiscal year 2024: -$280.37 million | Fiscal year 2023: -$149.49 million | Fiscal year 2022: -$86.11 million | Fiscal year 2021: -$45.82 million | Fiscal year 2020: -$16.91 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: